Equities Analysts Issue Forecasts for uniQure Q1 Earnings

uniQure (NASDAQ:QURE) – Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of uniQure in a note issued to investors on Thursday, February 27th. William Blair analyst S. Corwin anticipates that the biotechnology company will post earnings per share of ($1.39) for the quarter. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2026 earnings at ($1.41) EPS, Q3 2026 earnings at ($1.27) EPS and Q4 2026 earnings at ($1.22) EPS.

Several other research analysts have also weighed in on the company. Stifel Nicolaus upped their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Wells Fargo & Company reduced their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Finally, Mizuho raised their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $13.15 on Friday. The firm has a market cap of $640.73 million, a price-to-earnings ratio of -2.65 and a beta of 0.38. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a fifty day simple moving average of $15.05 and a 200 day simple moving average of $9.79.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. China Universal Asset Management Co. Ltd. grew its position in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the last quarter. Tudor Investment Corp ET AL grew its position in uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after buying an additional 1,371 shares in the last quarter. Wells Fargo & Company MN increased its stake in uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the period. Northern Trust Corp raised its holdings in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of uniQure by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after acquiring an additional 3,996 shares during the period. Institutional investors own 78.83% of the company’s stock.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,915 shares of company stock worth $588,112 in the last quarter. 4.74% of the stock is currently owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.